The FDA has approved SpringWorks Therapeutics’s mirdametinib (Gomekli) for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic ...

This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...

The goal of treatment for plexiform neurofibromas when they are diagnosed is to help that individual patient with how they're affecting them. So for many of those patients, those plexiform ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

“There are no treatments for many NF1 symptoms; current treatments for NF1 plexiform neurofibromas, such as surgery and MEK inhibitors, are helpful but come with their own set of trade ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib.

Among these tumors are cutaneous neurofibromas, benign tumors that grow from nerve terminals in the skin. Current treatment to reduce tumor growth in patients is limited to surgery, which can lead ...